Connor, Clark & Lunn Investment Management (CC&L)’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.54M | Buy |
69,614
+22,864
| +49% | +$1.49M | 0.02% | 602 |
|
|
2025
Q1 | $3.13M | Buy |
46,750
+31,308
| +203% | +$2.1M | 0.01% | 612 |
|
|
2024
Q4 | $854K | Buy |
15,442
+1,972
| +15% | +$109K | ﹤0.01% | 990 |
|
|
2024
Q3 | $804K | Buy |
13,470
+6,728
| +100% | +$401K | ﹤0.01% | 950 |
|
|
2024
Q2 | $429K | Sell |
6,742
-8,560
| -56% | -$545K | ﹤0.01% | 1088 |
|
|
2024
Q1 | $1.06M | Buy |
15,302
+6,867
| +81% | +$475K | ﹤0.01% | 870 |
|
|
2023
Q4 | $465K | Sell |
8,435
-877
| -9% | -$48.4K | ﹤0.01% | 1059 |
|
|
2023
Q3 | $541K | Buy |
+9,312
| New | +$541K | ﹤0.01% | 993 |
|